ProFACT Proteomics, Inc. Awarded New Jersey Incubator Seed Fund Grant
North Brunswick, NJ, July 24, 2008: The New Jersey Commission on Science and Technology announced that ProFACT Proteomics, Inc. is a recipient of a 2008 Incubator Seed Fund Grant. The funds will support development and filing of up to six new patents enhancing its platform tools in drug target and biomarker discovery.
About ProFACT Proteomics, Inc.
ProFACT Proteomics, Inc. is a privately held early-stage corporation which applies its enabling proprietary Proteomics technology, for development of therapeutics, diagnostics and personalized medicine, principally for cancer. Through partnership and service agreements, ProFACT offers SeraFILE™ for Functional Proteomics in four key areas for Drug and Biomarker development: 1) reduction of protein complexity and sub-proteome creation; 2) Rational Proteome Prospecting™, to enrich and isolate functional activity; 3) Conformerics™, to generate drug screening assays based on enzyme sub-states or conformers; and 4) Rational Genome to Proteome Prospecting™, for prospecting into protein expression based on gene expression data.
